Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Oncology

• Publication date

  2014-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2013.53.5633PMID 25154822PMCID PMC4162493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck : DAHANCA 6 and 7 randomised controlled trial

  2016cited by this paper
• Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma.

  2012cited by this paper
• Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma.

  2011cited by this paper
• Sensitivity analysis when data are missing not-at-random.

  2011cited by this paper
• Human papillomavirus and survival of patients with oropharyngeal cancer.

  2010cited by this paper
• Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

  2009cited by this paper
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

  2009cited by this paper
• Surrogate endpoints for overall survival in locally advanced head and neck cancer

  2009cited by this paper
• Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008influential reference
• Severe cutaneous reaction during radiation therapy with concurrent cetuximab.

  2007cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Fully conditional specification in multivariate imputation

  2006cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase*

  2005cited by this paper
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

  2003cited by this paper
• Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.

  2003cited by this paper
• C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.

  2003cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

  2000cited by this paper
• In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  2000cited by this paper
• Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.

  1999cited by this paper
• Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation

  1999cited by this paper
• Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

  1996cited by this paper
• Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

  1993cited by this paper
• Multiple imputation for nonresponse in surveys

  1989cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• The analysis of failure times in the presence of competing risks.

  1978cited by this paper
• The randomization and stratification of patients to clinical trials.

  1974cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Comparison of induction chemotherapy with/without PD-1 inhibitors followed by concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma

  2026cites this paper
• Treatment of P16-Negative/HPV-Negative Oropharyngeal Squamous Cell Carcinoma: A Survey of AHNS Membership.

  2026cites this paper
• Efficacy, safety, and survival outcomes of radiotherapy combined with nimotuzumab following induction chemotherapy in locally advanced head and neck cancer.

  2026cites this paper
• Systemic CYP3A inhibition by ritonavir enables selective targeting of hypoxic tumour cells by prodrugs of DNA-PK inhibitors

  2026cites this paper
• Beyond EGFR inhibition in Head and Neck Squamous Cell Carcinoma: overcoming resistance mechanisms and novel therapeutic frontiers.

  2026cites this paper
• Assumption-Lean Differential Variance Inference for Heterogeneous Treatment Effect Detection

  2025influential citation
• Cetuximab increases the risk of oral mucositis in radiotherapy-treated head and neck cancer compared to cisplatin: a systematic review of randomized controlled clinical trials

  2025cites this paper
• Impact of clinical and dosimetric factors on severe oral mucositis in head and neck cancer: insights from a phase II clinical trial

  2025cites this paper
• Managing Patients with Head and Neck Cancer and Advanced Age or Comorbidities.

  2025cites this paper
• Treatment outcomes for human papillomavirus negative oropharyngeal cancer: A meta-analysis.

  2025cites this paper
• The role of biomarkers in the management of HPV-related oropharyngeal cancer

  2025cites this paper
• Cáncer de orofaringe en Uruguay. Análisis de sobrevida en pacientes estadio III y IV tratados con radioterapia

  2025cites this paper
• Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC

  2025influential citation
• Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.

  2025cites this paper
• Evaluation of physical rehabilitation in patients receiving curative treatment for head and neck cancer: The NUTRIMOUV randomized phase II trial

  2025cites this paper
• Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.

  2025cites this paper
• Personalizing Approaches to Management of HPV+ Oropharyngeal Cancer

  2025cites this paper
• Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review

  2025cites this paper
• Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.

  2025cites this paper
• MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis

  2025cites this paper
• Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies

  2025cites this paper
• A systematic review of salivary gland hypofunction and/or xerostomia induced by non-surgical cancer therapies: prevention strategies

  2025cites this paper
• Randomized Clinical Trial of Geriatric Comanagement Versus Geriatric Assessment-Guided Supportive Care for Older Patients With Head and Neck Cancer.

  2025cites this paper
• Surgery for the Treatment of HPV‐Negative Oropharyngeal Squamous Cell Carcinoma—A Systematic Review and Meta‐Analysis

  2025cites this paper
• TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.

  2025cites this paper
• Treatment outcomes in p16-negative oropharyngeal squamous cell carcinoma (OPSCC): A real-world retrospective data from a low-middle income countries (LMIC).

  2025cites this paper
• Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.

  2025cites this paper
• Long term feeding tube use in head and neck cancer survivors - a secondary analysis of patient and treatment related factors.

  2025cites this paper
• Accuracy of an articulated head-and-neck motion model using deep learning-based instance segmentation of skeletal bones in CT scans for image registration in radiotherapy

  2025cites this paper
• IS THERE A PROGNOSTIC ROLE OF FOCAL ADHESION KINASE AND CD8 IN SQUAMOUS CELL HEAD AND NECK CANCER TREATED WITH RADIOTHERAPY?

  2025cites this paper
• Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16‐Negative Oropharyngeal Cancers

  2025cites this paper
• Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.

  2025cites this paper
• EIF3B stabilizes MAP2K2 to activate the ERK pathway and promote the progression of laryngeal squamous cell carcinoma

  2025cites this paper
• Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer

  2025cites this paper
• Subject-specific modeling framework for particle deposition using computational fluid dynamics

  2025cites this paper
• Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study

  2025cites this paper
• A comparative study to assess local control and toxicity in patients with high-risk head and neck squamous cell carcinoma treated with post-operative adjuvant concurrent chemoradiotherapy using cisplatin versus docetaxel and cetuximab

  2025cites this paper
• Application of a preclinical 18-gene classifier to patients with locally advanced HNSCC

  2025cites this paper
• Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

  2025cites this paper
• A systematic review and network meta-analysis of therapies for locally advanced head and neck squamous cell carcinoma with different HPV status

  2025cites this paper
• Assessment of Brachial Plexus Dose and Associated Toxicity in Nasopharyngeal Carcinoma Radiotherapy

  2025cites this paper
• Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.

  2025cites this paper
• Management of oropharyngeal squamous cell carcinoma: 2025 update.

  2025cites this paper
• Prognostic Implications of HPV Cell-Free DNA Serial Testing During Follow-Up of p16 Positive Oropharyngeal Squamous Cell Carcinoma After Curative-Intent Treatment.

  2025cites this paper
• Principles and Paradigms of De-Escalated Elective Nodal Irradiation: Boldly Going Towards an Inflection Point in Head and Neck Radiotherapy.

  2025cites this paper
• Brachial Plexopathy in Head and Neck Cancer Potentially Related to LET-Dependent RBE

  2025cites this paper
• Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus–Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial

  2025cites this paper
• Computational multiphysics modeling of radioactive aerosol deposition in diverse human respiratory tract geometries

  2024cites this paper
• Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Calreticulin-driven autophagy enhances cell proliferation in laryngeal squamous cell carcinoma.

  2024cites this paper
• Nomogram to predict risk of early mortality following definitive or adjuvant radiation and systemic therapy for head and neck cancer

  2024influential citation
• Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth

  2024cites this paper
• Pharmacogenomics and Big Data in medical oncology: developments and challenges

  2024cites this paper
• Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.

  2024cites this paper
• INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA.

  2024cites this paper
• Gingerol acts as a potent radiosensitizer in head and neck squamous cell carcinoma

  2024cites this paper
• Missed Adjuvant Therapy in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma

  2024cites this paper
• Improving Uncertainty-Error Correspondence in Deep Bayesian Medical Image Segmentation

  2024cites this paper
• Impact of radiotherapy-related late toxicities of skin and soft tissue in the neck on quality of life in head and neck cancer patients: a multi-institutional observational study in Japan

  2024cites this paper
• MUsculo-Skeleton-Aware (MUSA) deep learning for anatomically guided head-and-neck CT deformable registration

  2024cites this paper
• DNA methylation profiles of cancer-related fatigue associated with markers of inflammation and immunometabolism

  2024cites this paper
• Potential Transcript-Based Biomarkers Predicting Clinical Outcomes of HPV-Positive Head and Neck Squamous Cell Carcinoma Patients

  2024influential citation
• Reirradiation in head and neck squamous cell carcinoma; prognostic indicators, oncologic and functional outcomes.

  2024cites this paper
• Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials

  2024influential citation
• SAROS: A dataset for whole-body region and organ segmentation in CT imaging

  2024cites this paper
• Genetic variations associated with telomere length predict the risk of recurrence of non‐oropharyngeal head and neck squamous cell carcinoma

  2024cites this paper
• A feasibility study on the implementation of head and neck adaptive radiotherapy. A single centre’s experience

  2024cites this paper
• Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma

  2024cites this paper
• Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.

  2024cites this paper
• From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases

  2024cites this paper
• The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

  2024cites this paper
• A Network Meta-Analysis of the Systemic Therapies in Unresectable Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Oropharyngeal cancer and human papillomavirus: a visualization based on bibliometric analysis and topic modeling

  2024cites this paper
• Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials

  2024cites this paper
• Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.

  2024cites this paper
• Immunological Signatures for Early Detection of Human Head and Neck Squamous Cell Carcinoma through RNA Transcriptome Analysis of Blood Platelets

  2024cites this paper
• Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real‐world study

  2024cites this paper
• Identification of Down-Expressed CRNN Associated with Cancer Progression and Poor Prognosis in Laryngeal Squamous Cell Carcinoma.

  2024cites this paper
• Multi-organ segmentation of organ-at-risk (OAR's) of head and neck site using ensemble learning technique.

  2024cites this paper
• RADCURE: An open-source head and neck cancer CT dataset for clinical radiation therapy insights.

  2024cites this paper
• Efficacy of Depatuxizumab Mafodotin (ABT-414) in preclinical models of head and neck cancer.

  2024cites this paper
• Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020

  2024cites this paper
• Divergent Clinical Equivalence Findings from DVH and NTCP Metrics for Alternative OAR Delineations with Increasing Setup Variability in Head-and-Neck Radiotherapy

  2024cites this paper
• Combinatorial Approaches for Chemotherapies and Targeted Therapies with Radiation: United Efforts to Innovate in Patient Care.

  2024cites this paper
• Progression of Immunotherapy for Locally Advanced Head and Neck Tumors

  2024cites this paper
• Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.

  2024cites this paper
• A comparison of knowledge-based dose prediction approaches to assessing head and neck radiotherapy plan quality

  2024cites this paper
• Tube feeding in patients with head and neck cancer undergoing chemoradio-/radio therapy: A systematic review and meta-analysis based on the GRADE approach

  2024cites this paper
• Review and recommendations on deformable image registration uncertainties for radiotherapy applications

  2023cites this paper
• Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.

  2023cites this paper
• Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study

  2023cites this paper
• Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study

  2023cites this paper
• Dose difference between anisotropic analytical algorithm (AAA) and Acuros XB (AXB) caused by target’s air content for volumetric modulated arc therapy of head and neck cancer

  2023cites this paper
• Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.

  2023cites this paper
• REST-restrained lncRNA EPB41L4A-AS2 modulates laryngeal squamous cell carcinoma development via regulating miR-1254/HIPK2 pathway.

  2023cites this paper
• Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors

  2023cites this paper
• Late laryngeal dysfunction in head and neck cancer survivors

  2023cites this paper
• Dosimetric investigation of radiation‐induced trigeminal nerve toxicity in parotid tumor patients

  2023cites this paper
• Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.

  2023cites this paper